Novartis Presents ASCO Data Showing Kisqali’s Efficacy and Tolerability in High-Risk Early Breast Cancer Patients

Kisqali Benefit Lasts Across Age in Breast Cancer Subset

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.

Viz.ai, Novartis partner for AI-powered care for patients with cancer

Viz.ai, a company involved in AI-backed imaging and care coordination, is collaborating with pharma giant Novartis to develop proprietary AI-powered workflows inside the Viz Oncology Suite.Viz.ai offers a care coordination platform featuring over 50 FDA-cleared algorithms that help analyze medical imaging data to provide insights into diagnosis, ease workflows and support treatment decisions.  The companies will focus on improving the “identific…

Ribociclib/NSAI Shows Consistent Benefit in Early HR+/HER2– Breast Cancer

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Novartis Presents ASCO Data Showing Kisqali’s Efficacy and Tolerability in High-Risk Early Breast Cancer Patients

Novartis Presents ASCO Data Showing Kisqali’s Efficacy and Tolerability in High-Risk Early Breast Cancer Patients (IN BRIEF) Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in pre-menopausal patients with high-risk early breast cancer. The data reveals a 33% reduction in the relative risk of invasive disease for pre-menopausal patients receiving Kisqali …

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.